TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12968985

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg intravenous bolus followed by 1.0 or 1.25 mg/kg subcutaneously twice a day)
Number of subjects: 448
Study: 10839911

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40
Study: 9332966

Group type: EXPERIMENTAL
Intervention: Guía plus mood management intervention (Tomando Control de su Vida)
Number of subjects: 136
Study: 1596501

Group type: EXPERIMENTAL
Intervention: Se-rich bread providing 100 micrograms Se daily for 6 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Se-rich bread providing 200 micrograms Se daily for 6 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Se-rich bread providing 300 micrograms Se daily for 6 weeks
Number of subjects: 18
Study: 3880521

Group type: EXPERIMENTAL
Intervention: Bepridil (400 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29562927

Group type: EXPERIMENTAL
Intervention: 150 minutes/week of aerobic exercise (MODERATE)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 300 minutes/week of aerobic exercise (HIGH)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both MODERATE and HIGH groups
Number of subjects: 400
Study: 27716172

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib QD
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib BID
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 1% tofacitinib QD
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib QD and BID, 1% tofacitinib BID
Number of subjects: 435

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 435
Study: 24595778

Group type: EXPERIMENTAL
Intervention: Low-poverty voucher group (n=1430)
Number of subjects: 3689

Group type: EXPERIMENTAL
Intervention: Traditional voucher group (n=1081)
Number of subjects: 3689

Group type: COMPARATOR
Intervention: Control group (n=1178)
Number of subjects: 3689
Study: 23760519

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided bilateral rectus sheath block (BRSB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Local anesthetic infiltration (LAI)
Number of subjects: 52
Study: 20020207

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 22

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 22
Study: 17716819

Group type: EXPERIMENTAL
Intervention: Graded in vivo exposure
Number of subjects: 44

Group type: COMPARATOR
Intervention: Graded activity
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study: 17148518

Group type: EXPERIMENTAL
Intervention: Constraint‐Induced Movement Therapy plus donepezil (CIMT‐6 study)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Constraint‐Induced Movement Therapy plus repetitive transcranial magnetic stimulation (CIMT‐1 study)
Number of subjects: 39
Study: 14569738

Group type: COMPARATOR
Intervention: 400 mg daily of vaginally administrated Cyclogest (progesterone) alone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 400 mg daily of vaginally administrated Cyclogest (progesterone) in combination with 2 mg daily of oral Oestradiol Valerate (E2V)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 400 mg daily of vaginally administrated Cyclogest (progesterone) with E2V
Number of subjects: 118
Study: 12175626

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isosorbide mononitrate (IsMn)
Number of subjects: 52
Study: 10355235

Group type: EXPERIMENTAL
Intervention: Lexical decision to the prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading the prime silently
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naming the prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short (120-msec) prime-target stimulus onset asynchrony
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Associative prime processing
Number of subjects: 0
Study: 7717558

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epidural anesthesia with lidocaine
Number of subjects: 10
Study: 2285437

Group type: EXPERIMENTAL
Intervention: Early discharge (12 to 24 hours)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Early discharge (25 to 48 hours)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (4 days)
Number of subjects: 131
Study: 6813360

Group type: EXPERIMENTAL
Intervention: acebutolol (mean dose 913 mg/day) during single-blind phase
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: acebutolol (mean dose 968 mg/day) during double-blind phase
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: acebutolol during single-blind phase
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo during double-blind phase
Number of subjects: 25
Study: 31093649

Group type: EXPERIMENTAL
Intervention: Tenofovir monoester
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Plasma tenofovir
Number of subjects: 24
Study: 29261248

Group type: EXPERIMENTAL
Intervention: Social Work Intervention Focused on Transitions (up to 2 in-home visits and up to 4 telephone follow-up calls)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Opting out of the intervention (refusal of home visit component)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Opting out of the intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Having a diagnosis of cancer
Number of subjects: 90
Study: 26242435

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 3 minutes after delivery
Number of subjects: 105

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) at around 1 minute after delivery
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 105
Study: 25782323

Group type: COMPARATOR
Intervention: Traditional monitoring (Group 1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Rheumatologist visits every 12 weeks (Group 2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Telephone counseling once every 4 weeks (Group 3)
Number of subjects: 168
Study: 22735077

Group type: EXPERIMENTAL
Intervention: CST training and outreach support
Number of subjects: 0

Group type: COMPARATOR
Intervention: CST training only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring centres running groups in usual practice
Number of subjects: 0
Study: 19318471

Group type: EXPERIMENTAL
Intervention: gp100(209‐2M) vaccination
Number of subjects: 0
Study: 17462655

Group type: EXPERIMENTAL
Intervention: Plate-mounted marker group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Strap-mounted marker group
Number of subjects: 10
Study: 15698940

Group type: EXPERIMENTAL
Intervention: Calcium 1 g + Vitamin D 800 IU daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12693587

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin 240 mg and mefloquine 1,250 mg given over 3 days (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydroartemisinin 240 mg and azithromycin 1,500 mg given over 3 days (Group 2)
Number of subjects: 0
Study: 9714943

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral multidisciplinary pain management program
Number of subjects: 0
Study: 7982362

Group type: EXPERIMENTAL
Intervention: Intervention group mothers (enhanced maternal sensitive responsiveness)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intervention infants
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intervention group dyads
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group mothers
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group dyads
Number of subjects: 2
Study: 2920667

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 ml of pure alcohol/kg body weight)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 4555651

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 48
Study: 29303777

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (12 sessions, 90 mw, 1 min per acupoint, total energy 5.4 joules per acupoint, 21.6 joules to ashi points, wavelength 808 nm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham laser (laser probe directed to acupoints while the device is off)
Number of subjects: 40
Study: 27590788

Group type: EXPERIMENTAL
Intervention: Multiple periods of outdoor free play (3 periods of at least 15 minutes each)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single period of outdoor play (control group)
Number of subjects: 14
Study: 24839884

Group type: EXPERIMENTAL
Intervention: 1.3 grams of omega-3 fatty acids daily for 6 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Identical placebo daily for 6 weeks
Number of subjects: 57
Study: 23514054

Group type: EXPERIMENTAL
Intervention: Laparoscopic peptic ulcer repair (LR)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Open peptic ulcer repair (OR)
Number of subjects: 115
Study: 19648905

Group type: EXPERIMENTAL
Intervention: SICS
Number of subjects: 160

Group type: COMPARATOR
Intervention: CECS
Number of subjects: 160
Study: 17457340

Group type: EXPERIMENTAL
Intervention: Plant-based dietary portfolio (high in plant sterols 1.0 g/1000 kcal, soy protein 22.5 g/1000 kcal, viscous fibers 10 g/1000 kcal, almonds 22.5 g/1000 kcal)
Number of subjects: 66
Study: 16837543

Group type: EXPERIMENTAL
Intervention: Trabeculotomy ab externo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 8
Study: 12940842

Group type: EXPERIMENTAL
Intervention: Three or more modifiable vascular risk factors
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid stenosis (ACS) of 50% or greater
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Modifiable vascular risk factors
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hypertension and cardiac diseases
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cardiac diseases and obesity
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ACS and high low-density lipoprotein (LDL) cholesterol levels
Number of subjects: 500
Study: 10679756

Group type: EXPERIMENTAL
Intervention: 3-month neoadjuvant LH-RH-analogue treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 103
Study: 9275141

Group type: EXPERIMENTAL
Intervention: Aqueous wheat flour extract inhalation at concentrations of 0.01, 0.1, 1, 10, and 100 mg/ml for 10 minutes.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Wheat flour dust inhalation from Spinhaler capsules (1, 2, or 4 capsules, maximum of 7 cumulative capsules).
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (atopic subjects) inhaling wheat flour dust from capsules.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both methods (aqueous extract and dust inhalation).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Only subjects with a positive skin test response to wheat flour.
Number of subjects: 36
Study: 8148487

Group type: EXPERIMENTAL
Intervention: Tamoxifen (89 patients, treated group)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (60 patients, controls)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Current users of tamoxifen (n = 18)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ex-users of tamoxifen (n = 71)
Number of subjects: 149
Study: 3094919

Group type: EXPERIMENTAL
Intervention: Epidural morphine (Group E)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous morphine (Group I)
Number of subjects: 13
Study: 2568211

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 12.5 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 25 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 50 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 75 micrograms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 5
Study: 31722820

Group type: EXPERIMENTAL
Intervention: Midazolam (buccal, intranasal or intramuscular)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam or Diazepam (IV agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin (and its prodrug fosphenytoin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study: 30293408

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic resistance training (IHRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normoxia (FIO2=21%)
Number of subjects: 25
Study: 27436368

Group type: EXPERIMENTAL
Intervention: Hemostatic suture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bipolar electrocoagulation
Number of subjects: 90
Study: 25465924

Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 433
Study: 22545977

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Psychoeducational seminar
Number of subjects: 65
Study: 20924913

Group type: EXPERIMENTAL
Intervention: Computer training program for memory improvement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard group treatment
Number of subjects: 30
Study: 19536890

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 225
Study: 16614150

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Embolosphere Gold
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Contour SE
Number of subjects: 50
Study: 12093941

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Surgery (both tonsillectomy and adenotonsillectomy)
Number of subjects: 328
Study: 10748773

Group type: EXPERIMENTAL
Intervention: Irrigation suction drainage (ISD) with 6000 ml of saline solution per day for 7 or more days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Irrigation suction drainage (ISD) with 2000 ml of saline solution per day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Irrigation suction drainage (ISD) with 6000 ml of saline solution per day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Irrigation suction drainage (ISD)
Number of subjects: 105
Study: 7723966

Group type: EXPERIMENTAL
Intervention: Stereotactic ventral pallidotomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (nonsurgically treated)
Number of subjects: 18
Study: 1915807

Group type: EXPERIMENTAL
Intervention: alpha interferon
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: monthly 5 day courses with thioguanine and cytarabine
Number of subjects: 108

Group type: COMPARATOR
Intervention: nothing (control)
Number of subjects: 108
Study: 7250173

Group type: EXPERIMENTAL
Intervention: Ibopamine hydrochloride (SB 7505) at doses starting from 100 mg to 350 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibopamine hydrochloride (SB 7505)
Number of subjects: 12
Study: 31020400

Group type: EXPERIMENTAL
Intervention: Pole Walking (PW)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Walking (W)
Number of subjects: 14
Study: 28351163

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 30
Study: 26521223

Group type: EXPERIMENTAL
Intervention: Group physical activity and diet educational program
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 332
Study: 23815891

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (intervention group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (intervention group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21944133

Group type: EXPERIMENTAL
Intervention: Tamsulosin (various doses)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Tamsulosin (low dose)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Tamsulosin (medium dose)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Tamsulosin (high dose)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Tamsulosin and Placebo
Number of subjects: 161
Study: 18272935

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 74
Study: 16691043

Group type: EXPERIMENTAL
Intervention: Yakson therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: GHT therapy
Number of subjects: 29
Study: 12928048

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined patient and control groups
Number of subjects: 25
Study: 17536290

Group type: EXPERIMENTAL
Intervention: Intermittent Pulsatile Compression (IPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Slow Sequential Compression (SCD)
Number of subjects: 20
Study: 8629747

Group type: EXPERIMENTAL
Intervention: IV ketamine (0.2 mg/kg bolus followed by 0.5 mg/kg/hour infusion for 3 hours, adjusted to 0.1 mg/kg bolus for the first 9 patients)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (bolus and infusion for 3 hours)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: IV ketamine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: COMPARATOR
Intervention: IV ketamine and Placebo
Number of subjects: 53
Study: 1310465

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 20
Study: 6658721

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg given perorally three times a day for three months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 31795283

Group type: EXPERIMENTAL
Intervention: Cinnamate esters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QSAR modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular descriptors analysis
Number of subjects: 0
Study: 29730198

Group type: EXPERIMENTAL
Intervention: Deferred radical prostatectomy
Number of subjects: 132
Study: 25263242

Group type: EXPERIMENTAL
Intervention: HSS 3% with epinephrine (3 mL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: HSS 3% with placebo (3 mL)
Number of subjects: 64
Study: 25711836

Group type: EXPERIMENTAL
Intervention: Mesoglycan 50 mg twice daily for 90 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study: 23669880

Group type: EXPERIMENTAL
Intervention: Cycle training (8 weeks of increasing intensity stationary cycle training)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cycle training
Number of subjects: 18
Study: 20063429

Group type: EXPERIMENTAL
Intervention: Baseline uric acid levels
Number of subjects: 347
Study: 18718966

Group type: EXPERIMENTAL
Intervention: Orexin A intranasally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16847549

Group type: EXPERIMENTAL
Intervention: 0.82 g/kg dose of alcohol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12742478

Group type: EXPERIMENTAL
Intervention: Sirolimus, cyclosporine microemulsion formulation, and prednisone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sirolimus-based protocol with decreased calcineurin inhibitors
Number of subjects: 81
Study: 10803800

Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg three times daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: tolcapone withdrawal
Number of subjects: 59
Study: 9107558

Group type: EXPERIMENTAL
Intervention: Euphytose (EUP) - two tablets three times a day over 28 days
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo - two tablets three times a day over 28 days
Number of subjects: 182
Study: 1547052

Group type: EXPERIMENTAL
Intervention: Positive therapeutic suggestions (tapes)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Modified history of the Queen's Medical Centre (tapes)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 75
Study: 2865746

Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 299

Group type: COMPARATOR
Intervention: 20 mg temazepam
Number of subjects: 299
Study: 30314747

Group type: EXPERIMENTAL
Intervention: Covert observation of hand hygiene compliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methods of hand hygiene compliance monitoring
Number of subjects: 0
Study: 30463831

Group type: EXPERIMENTAL
Intervention: Methyl carprost suppository combined with oxytocin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oxytocin (control group)
Number of subjects: 180
Study: 27248440

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (10 mg enalapril)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25148302

Group type: EXPERIMENTAL
Intervention: Paired sets with minimal allowable rest (PMR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: P30 - 30-second rest between paired sets
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: P1 - 1-minute rest between paired sets
Number of subjects: 15
Study: 22767495

Group type: EXPERIMENTAL
Intervention: dance-based exergaming
Number of subjects: 40

Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 40